organization · Reporting owner
PF Equity Holdings 2 B.V.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allogene Therapeutics, Inc.
Report date March 31, 2022 · Filed April 04, 2022
Section 16 reporting ended · disclosed 2022-04-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-03-31 transaction · row 1
1 source rowRow 1 · 2022-03-31 · Other · Disposed 22,032,040 · Balance 0 F1: Shares transferred to its parent entity, Pfizer Inc., for no cash consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares transferred to its parent entity, Pfizer Inc., for no cash consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2022 Filed Apr 4, 2022 16:44 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 22,032,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001883111-22-000001 · primary_doc.xml · nonDerivative · entry 1 PF Equity Holdings 2 B.V. · CIK 0001883111 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares transferred to its parent entity, Pfizer Inc., for no cash consideration. F1 · shares: Shares transferred to its parent entity, Pfizer Inc., for no cash consideration. F1 · price: Shares transferred to its parent entity, Pfizer Inc., for no cash consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.